Select Scientific POSTERS

RevIEW POSTERS BY YEAR

2017

Quantification of Rare PD-L1 and Other Immunology Biomarker Expressing Leukocytes and CTCs in Peripheral Blood of Cancer Patients. EORTC

Comprehensive Single Cell Analysis of Tumor Mutation Burden (TMB), Chromosomal Instability (CIN), and Microsatellite Instability (MSI) on Circulating Tumor Cells (CTCs). EORTC

Phenotypic Circulating Tumor Cell (CTC) Classifier of Genomic Instability (GI) Associates with Improved Overall Survival (OS) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts) Receiving Platinum Agents in Addition to Taxanes. ESMO 

Integrated Single Cell Phenogenomic Subtyping of CTCs Identify Inter-Cellular Tumor Heterogeneity (het) and Multiple Resistance Mechanisms in mCRPC Patients (pts). ASCO GU 

Quantification of Rare PD-L1 and Other Immunology Biomarker Expressing Leukocytes and CTCs in Peripheral Blood of Cancer Patients. AACR 

Phenotypic, Genomic, and Clinical Associations of Circulating Tumor Cells (CTCs) Lacking Epithelial Biomarkers in Metastatic Castration Resistant Prostate Cancer (mCRPC). AACR

Changes in CTC burden and phenotypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapeutics (Tx)

Baseline Circulating Tumor Cell (CTC) Subtype Predicts Responses to Enzalutamide but Not Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) prognosticates poor overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with androgen receptor signaling inhibitors (ARSi)

Review posters by Indication

Breast cancer studies                         Prostate cancer studies

 

Lung cancer studies                           Bladder cancer studies

 

 
 
 
 
 
 
 

Our mission is to improve patient lives by enabling precision medicine with non-invasive tests that profile rare cells in cancer.